Disclosure Quest - Search SEC Filings

Name	Type of Offering	Accepted Date
SIAMAB THERAPEUTICS, INC. See All Filings	D	2018-11-08 16:16:09 UTC
Amount To Be Raised $2,000,000 Associated Brokers / Dealers N/A CIK Number 0001351615 Filed Document 0001351615-18-000001 Exclusions or Exemptions 506b Accepted Date 2018-11-08 16:16:09 UTC Type of Offering D Industry Biotechnology Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Debt
SIAMAB THERAPEUTICS, INC. See All Filings	D/A	2016-03-29 00:00:00 UTC
Amount To Be Raised $7,000,000 Associated Brokers / Dealers N/A CIK Number 0001351615 Filed Document 0001351615-16-000003 Exclusions or Exemptions 506b Accepted Date 2016-03-29 00:00:00 UTC Type of Offering D/A Industry Biotechnology Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
SIAMAB THERAPEUTICS, INC. See All Filings	D	2015-04-01 00:00:00 UTC
Amount To Be Raised $4,000,352 Associated Brokers / Dealers N/A CIK Number 0001351615 Filed Document 0001351615-15-000001 Exclusions or Exemptions 506b Accepted Date 2015-04-01 00:00:00 UTC Type of Offering D Industry Biotechnology Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
SIAMAB THERAPEUTICS, INC. See All Filings	D	2014-07-09 00:00:00 UTC
Amount To Be Raised $1,500,000 Associated Brokers / Dealers N/A CIK Number 0001351615 Filed Document 0001351615-14-000004 Exclusions or Exemptions 506b Accepted Date 2014-07-09 00:00:00 UTC Type of Offering D Industry Biotechnology Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
Sialix, Inc. See All Filings	D/A	2014-02-26 00:00:00 UTC
Amount To Be Raised $2,522,569 Associated Brokers / Dealers N/A CIK Number 0001351615 Filed Document 0001351615-14-000001 Exclusions or Exemptions 506b Accepted Date 2014-02-26 00:00:00 UTC Type of Offering D/A Industry Biotechnology Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity